Global X China Biotech Innovation ETF (CHB)

NASDAQ: CHB · IEX Real-Time Price · USD
-0.09 (-1.11%)
At close: Dec 5, 2023, 9:45 AM
+0.08 (0.99%)
After-hours: Dec 5, 2023, 4:15 PM EST
Assets $2.30M
Expense Ratio 0.65%
PE Ratio 16.34
Shares Out n/a
Dividend (ttm) $0.04
Dividend Yield 0.46%
Ex-Dividend Date Jun 29, 2023
Payout Ratio 7.60%
1-Year Return -14.86%
Volume 145
Open 8.05
Previous Close 8.14
Day's Range 8.05 - 8.05
52-Week Low 7.11
52-Week High 11.08
Beta n/a
Holdings 45
Inception Date Sep 22, 2020

About CHB

Fund Home Page

The Global X China Biotech Innovation ETF (CHB) is an exchange-traded fund that is based on the Solactive China Biotech Innovation index. The fund tracks a market-cap weighted index of Chinese companies that are involved in the biotechnology industry. CHB was launched on Sep 22, 2020 and is issued by Global X.

Asset Class Equity
Category China Region
Region Asia-Pacific
Stock Exchange NASDAQ
Ticker Symbol CHB
ETF Provider Global X
Index Tracked Solactive China Biotech Innovation Index

Top 10 Holdings

60.73% of assets
Name Symbol Weight
CSPC Pharmaceutical Group Ltd 1093.HK 8.44%
Chongqing Zhifei Biological Products Co Ltd Class A 300122.SZ 8.38%
Changchun High and New Technology Industry Group Inc Class A 000661.SZ 8.18%
WuXi Biologics (Cayman) Inc 2269.HK 6.73%
Walvax Biotechnology Co Ltd Class A 300142.SZ 6.24%
Shanghai RAAS Blood Products Co Ltd Class A 002252.SZ 5.02%
Beijing Tiantan Biological Products Corp Ltd Class A 600161.SS 4.84%
Sichuan Kelun Pharmaceutical Co Ltd Class A 002422.SZ 4.45%
Hualan Biological Engineering Inc Class A 002007.SZ 4.35%
Genscript Biotech Corp Class H 1548.HK 4.11%
View More Holdings


Ex-Dividend Amount Pay Date
Jun 29, 2023 $0.03703 Jul 10, 2023
Jun 29, 2022 $0.01989 Jul 8, 2022
Full Dividend History


Capture the Growth Potential in China's Biotech Sector With This ETF

With China's economy recovering from a real estate development crisis and rising COVID-19 cases in 2022, it only sets up growth potential for 2023. One area of interest that exchange-traded fund (ETF)...

1 year ago - ETF Trends

Capitalize on Biotech Growth in China With This ETF

After a rough 2021 that featured the Evergrande Crisis and heavy regulatory measures on technology to keep monopolistic moves in check, investors are eyeing opportunities in China. One of the sectors ...

1 year ago - ETF Trends

This Week's Top Performing ETFs: 06/19/2022

Top Performing Unleveraged ETFs Last Week These were last week's top-performing ETFs. We've excluded funds that use leverage or make inverse bets on their underlying assets.

1 year ago - ETF Trends

Innovation Should Help Fuel Growth in This China Biotech ETF

Growth opportunities are abounding in Chinese biotech. A confluence of regulatory reforms, industry talent, and the re-opening of the country's capital markets have helped propel China's biotech indus...

1 year ago - ETF Trends

The CHB ETF: China's Burgeoning Biotech Sector

As China continues to lead the global recovery, one area to keep a close eye on is biotechnology and the Global X China Biotech Innovation ETF (CHB). CHB seeks to provide investment results that corre...

2 years ago - ETF Trends

ETF Odds & Ends: First Mutual Fund Conversion

Plus, iShares lowered expense ratios on two of its ETFs.

2 years ago - ETFcom

China's Quest for a Covid-19 Vaccine Could Help Boost This ETF

All around the world, economic superpowers are vying to be the first to develop a vaccine for Covid-19. China is an obvious contender given that the country was the epicenter of the virus and their su...

3 years ago - ETF Trends